Medicane Health Overview
MediCane Health is an international pharmaceutical company engaged in the research, development, production, and marketing of cannabis-based medications. With operational subsidiaries in Israel, Portugal, and a commercial hub in Germany, the company focuses on European countries that promote legislation for medical cannabis. MediCane aims to advance medical research and development in different therapeutic areas, exploring the connection between the use of cannabis plant components and improving the health of patients with various medical conditions. MediCane wishes to contribute to the symptom relief of people whose needs cannot be met through traditional drug treatments. MediCane develops products in two parallel regulatory pathways: the medical cannabis route, using whole plant extractions, and the pharmaceutical route, using isolated ingredients. MediCane controls the seed-to-customer value chain to ensure delivery of its highest quality pharmaceutical-grade products to patients in need. MediCane conducts various clinical trials in collaboration with scientists and physicians in different fields, with the support of academic research institutions and hospitals in Israel, UK, Portugal, Spain, and more.
Latest News
MediCane Health Inc. Announce First Patient Enrolled in a Phase IIa Clinical Trial of MediCane's Balanced T3:C3 Oral Medical Cannabis Oil for Symptom Relief of Behavioral and Psychological Symptoms of Dementia (BPSD)
growth-positive
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
Dr. Reddys Laboratories Ltd. and MediCane Health Inc. have announced the launch of their medical cannabis product in Germany. This is part of a collaboration that started in 2021, where MediCane will supply the medical cannabis products to Dr. Reddys from its EU-GMP-certified facilities in Portugal. The launch marks MediCanes entry into the pharmaceutical sector of a major European market and reinforces Dr. Reddys presence in Germanys growing medical cannabis market. The companies have also signed an agreement for the co-funding of a phase II clinical trial for a cannabis product aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD).
PartnersExpand
MediCane Health Inc. Receives EU GMP License for its manufacturing plant in Portugal
growth-positive
The first social media for cannabis patients launched
EcoCaNN, the first social media platform for medical cannabis patients, has been officially launched in Israel. The app allows patients and their families to consult with professionals in the medical cannabis field and get specific answers to their questions. EcoCaNN was established by MediCane, an international pharma company focused on the research and development of medical cannabis-based pharmaceutical medicines. The app aims to provide accurate information and support for patients, as well as assist doctors and researchers in their R&D efforts. EcoCaNN is based on the technology of Belong.life and will be launched in selected countries in English and other languages in regions where medical cannabis is allowed.
CustomersPartners
growth-positive
Israeli cannabis startup MediCane Health is looking to compete with big pharma
Ziv Aviram, co-founder of Mobileye, OrCam, and Active Chairman of MediCane Health, discusses the progress of his cannabis pharma company and its plans to go public on Wall Street. MediCane Health, which develops cannabis-based medicine, recently inaugurated its new lab and is expecting to release its first cannabis-based drug for dementia patients. Aviram emphasizes that the companys goal is to become a successful pharmaceutical company and is focused on research and development. The company is waiting for necessary approvals, collaboration with a large international pharmaceutical company, and the removal of cannabis from the list of banned substances in the US before going public. MediCane Health has already expanded its operations in several medical cannabis markets and has distribution agreements with pharma distributors. The company has received $50 million in investments from private investors, including Aviram himself.
InvestmentPublic Trading
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
8
Employees: 11-50
Web & Social Links
| Website | medicane.net/ |
| Careers | Careers page |
Locations
Ha-Ta'as Street 28, Kefar Sava, Israel
Av. da Repblica 48b, Lisbon, Portugal
25 Bligh St, Sydney NSW, Australia
700 W Georgia St, Vancouver, BC, Canada
Photos & Videos
2 item(s)
Medicane Health Business
Business models
B2B, B2C
Product stage
Released
Employees
11-50
Sector
Agriculture & Food TechnologiesAg TechFarm Equipment & TreatmentHealth Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Materials & SubstancesRaw MaterialsTags (13)
biotechnologyneurologypharmaceuticalsacademiatherapeuticsbrain-disordertreatmentshospitalsdrug-developmentmedical-cannabisinflammatory-diseasesagtechcannabisGeographic Markets
East AsiaAustraliaEuropeIsraelUnited StatesMedicane Health Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Medicane Health Lifecycle
Medicane Health News
6 articlesMediCane Health Inc. Announce First Patient Enrolled in a Phase IIa Clinical Trial of MediCane's Balanced T3:C3 Oral Medical Cannabis Oil for Symptom Relief of Behavioral and Psychological Symptoms of Dementia (BPSD)
growth-positive
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
Dr. Reddys Laboratories Ltd. and MediCane Health Inc. have announced the launch of their medical cannabis product in Germany. This is part of a collaboration that started in 2021, where MediCane will supply the medical cannabis products to Dr. Reddys from its EU-GMP-certified facilities in Portugal. The launch marks MediCanes entry into the pharmaceutical sector of a major European market and reinforces Dr. Reddys presence in Germanys growing medical cannabis market. The companies have also signed an agreement for the co-funding of a phase II clinical trial for a cannabis product aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD).
PartnersExpand
MediCane Health Inc. Receives EU GMP License for its manufacturing plant in Portugal
growth-positive
The first social media for cannabis patients launched
EcoCaNN, the first social media platform for medical cannabis patients, has been officially launched in Israel. The app allows patients and their families to consult with professionals in the medical cannabis field and get specific answers to their questions. EcoCaNN was established by MediCane, an international pharma company focused on the research and development of medical cannabis-based pharmaceutical medicines. The app aims to provide accurate information and support for patients, as well as assist doctors and researchers in their R&D efforts. EcoCaNN is based on the technology of Belong.life and will be launched in selected countries in English and other languages in regions where medical cannabis is allowed.
CustomersPartners
growth-positive
Israeli cannabis startup MediCane Health is looking to compete with big pharma
Ziv Aviram, co-founder of Mobileye, OrCam, and Active Chairman of MediCane Health, discusses the progress of his cannabis pharma company and its plans to go public on Wall Street. MediCane Health, which develops cannabis-based medicine, recently inaugurated its new lab and is expecting to release its first cannabis-based drug for dementia patients. Aviram emphasizes that the companys goal is to become a successful pharmaceutical company and is focused on research and development. The company is waiting for necessary approvals, collaboration with a large international pharmaceutical company, and the removal of cannabis from the list of banned substances in the US before going public. MediCane Health has already expanded its operations in several medical cannabis markets and has distribution agreements with pharma distributors. The company has received $50 million in investments from private investors, including Aviram himself.
InvestmentPublic Trading
growth-positive
עסקי הקנאביס של זיו אבירם נחשפים
Ziv Aviram, co-founder of Mobileye, has entered the cannabis industry by founding MediCane Health, a pharmaceutical company focused on developing cannabis-based medications. The company aims to promote medical research in the field of health and is currently conducting clinical trials in collaboration with scientists, doctors, universities, and hospitals in several countries. MediCane Health plans to market its medical cannabis products in Israel, authorized European markets, Australia, and Far East countries that have legalized cannabis. The company is self-funded and aims to maintain financial independence and flexibility in the development process.
InvestmentExpand
Medicane Health Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 43 |
| Team members | 10 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Medicane Health Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 88/100 |
| Missing | founding month, funding rounds, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516125267 |
| Crunchbase | medicane-health |
| Phone | +972747695959 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-30T00:00:00.000Z |
| Created | 2021-01-26T00:00:00.000Z |